Investment details
Entry
Staff
5Location
USAOur goal is to build Kinaset into a leading respiratory therapeutics company focused on patients starting with KN-002.
Robert Clarke
CEO
Partnership Gimv Partnership Gimv Partnership Gimv
Partnership Gimv
The best-in-class profile and tailor-made dry powder formulation captured Gimv’s interest from the early start. Together with this very experienced and dedicated management team, Gimv is convinced KN-002 can make a real difference to severe asthma patients who have limited treatment options today.
Deal Team
News News News